DUBLIN – Vaccine maker Valneva SE and Glaxosmithkline plc have unwound the final strands of a longstanding alliance, leaving the smaller firm to go its own way with the two surviving assets from the agreement, a vaccine against Lyme disease, which is currently in phase II trials, and a vaccine against chikungunya virus, which has completed a phase I trial.